Results 41 to 50 of about 53,193 (289)

Physical-based optimization for non-physical image dehazing methods [PDF]

open access: yes, 2020
Images captured under hazy conditions (e.g. fog, air pollution) usually present faded colors and loss of contrast. To improve their visibility, a process called image dehazing can be applied.
Bertalmío, Marcelo   +2 more
core   +2 more sources

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

open access: yesFrontiers in Oncology, 2022
Patients with RET fusions represent 1-2% of all cases of non-small cell lung cancer (NSCLC), the majority of whom are younger, and are extremely rare in the elderly.
Li An   +9 more
doaj   +1 more source

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions

open access: yesCell Reports Medicine, 2022
The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-terminal motifs and is fused to GRB2, a physiological ...
Cynthia M. Estrada-Zuniga   +13 more
openaire   +3 more sources

KIF5B-RET fusions in lung adenocarcinoma [PDF]

open access: yesNature Medicine, 2012
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation ...
Takashi, Kohno   +28 more
openaire   +2 more sources

Pralsetinib treatment for multiple fusions in lung adenocarcinoma: a case report

open access: yesJournal of International Medical Research, 2022
Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection ( RET ) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been used
Xiangming Cao   +6 more
doaj   +1 more source

Architecture of coatomer: Molecular characterization of delta-COP and protein interactions within the complex [PDF]

open access: yes, 1996
Copyright © 2011 by The Rockefeller University Press.Coatomer is a cytosolic protein complex that forms the coat of COP I-coated transport vesicles.
Auerbach, S   +9 more
core   +1 more source

Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report

open access: yesFrontiers in Oncology
IntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and ...
Urpo Kiiskinen   +4 more
doaj   +1 more source

Singly generated quasivarieties and residuated structures [PDF]

open access: yes, 2019
A quasivariety K of algebras has the joint embedding property (JEP) iff it is generated by a single algebra A. It is structurally complete iff the free countably generated algebra in K can serve as A.
Anderson A. R.   +25 more
core   +2 more sources

Drosophila Cancer Models Identify Functional Differences between Ret Fusions

open access: yesCell Reports, 2016
We generated and compared Drosophila models of RET fusions CCDC6-RET and NCOA4-RET. Both RET fusions directed cells to migrate, delaminate, and undergo EMT, and both resulted in lethality when broadly expressed.
Sarah Levinson, Ross L. Cagan
doaj   +1 more source

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer

open access: yesHeliyon
Background: Rearranged during transfection (RET) gene fusion is a target for non-small cell lung cancer (NSCLC) treatment, and RET inhibitors are approved for advanced NSCLC.
Rui Wan   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy